Glomerulonephritis, Membranoproliferative clinical trials
The registry lists 33 studies for Glomerulonephritis, Membranoproliferative across more than 10 countries. 10 are recruiting or about to start. 24 of them are mainly about Glomerulonephritis, Membranoproliferative (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Glomerulonephritis, Membranoproliferative studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Apellis Pharmaceuticals, Inc. (5) · Mario Negri Institute for Pharmacological Research (5) · Alexion Pharmaceuticals, Inc. (4) · Novartis Pharmaceuticals (4) · University of Iowa (2) · Columbia University (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · UK Kidney Association (1)
What is being tested here
Drugs under test in Glomerulonephritis, Membranoproliferative studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Jul 2027An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis · Phase 3 · Apellis Pharmaceuticals, Inc.
- Dec 2026A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain · Novartis Pharmaceuticals
Who these studies take
Of the 9 Glomerulonephritis, Membranoproliferative studies recruiting now, 5 (56%) set no upper age limit and 0 (0%) stop at 75 or younger. 5 (56%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (11%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (33%) | 3 (33%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 9 (100%) | 9 (100%) |
| 50 | 9 (100%) | 9 (100%) |
| 65 | 9 (100%) | 9 (100%) |
| 75 | 9 (100%) | 9 (100%) |
| 85 | 9 (100%) | 9 (100%) |
Across all 33 studies, recruiting or not: 18% stop at 75 or younger and 15% at 65; 61% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Studies
Recruiting first, then most recently updated. Showing 33 of 33. search them.
- Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingNCT05795140Phase 36 countries
- A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant RecipientsRecruitingNCT07898774Phase 310 countries
- Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on Podocytes in Patients With C3G and Primary IC-MPGNNot yet recruitingNCT079043381 country
- A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainRecruitingNCT075984481 country
- Chinese Adults With Kidney DiseaseRecruitingNCT07522099Phase 21 country
- Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNRecruitingNCT03955445Phase 317 countries
- A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 GlomerulopathyRecruitingNCT074161621 country
- Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare DiseasesRecruitingNCT05996731Not applicable1 country
- Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 GlomerulopathyRecruitingNCT04183101Phase 21 country
- National Registry of Rare Kidney DiseasesRecruitingNCT060658521 country
- Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)TerminatedNCT05162066Phase 24 countries
- Synergetic B-cell Immunomodulation in SLE - 2nd Study.CompletedNCT03747159Phase 31 country
- Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNCompletedNCT04572854Phase 211 countries
- An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisActive, not recruitingNCT05809531Phase 315 countries
- New Analytic Tools for aHUS and C3G DiagnosisActive, not recruitingNCT05985122Not applicable1 country
- Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative GlomerulonephritisCompletedNCT05067127Phase 319 countries
- C3G/Primary IC-MPGN EAPApproved for marketingNCT04729062
- Controlled Trial Evaluating Avacopan in C3 GlomerulopathyCompletedNCT03301467Phase 211 countries
- Phase II Study Assessing Safety and Efficacy of APL-2 in GlomerulopathiesCompletedNCT03453619Phase 21 country
- A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471TerminatedNCT03459443Phase 25 countries
- Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With ProteinuriaCompletedNCT05314231Phase 11 country
- A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)CompletedNCT03369236Phase 22 countries
- Daratumumab in Treatment of PGNMID and C3 GNCompletedNCT03095118Phase 21 country
- Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 StudyCompletedNCT03723512Not applicable1 country
- A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGNCompletedNCT03124368Phase 23 countries
- Eculizumab Therapy for Dense Deposit Disease and C3 NephropathyCompletedNCT01221181Phase 11 country
- Eculizumab in Primary MPGNCompletedNCT02093533Phase 21 country
- Effect of Rituximab in Treatment of Membranoproliferative GlomerulonephritisStatus unknownNCT03180723Phase 3
- TP10 Use in Patients With C3 Glomerulopathy (C3G)WithdrawnNCT02302755Phase 11 country
- Sulodexide Treatment in Patients With Dense Deposit DiseaseWithdrawnNCT00583427Phase 11 country
- Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit DiseaseTerminatedNCT01791686Phase 11 country
- Pilot Study of Rituximab for Membranoproliferative GlomerulonephritisCompletedNCT00275613Phase 11 country
- BG9588 (Anti-CD40L Antibody) to Treat Lupus NephritisCompletedNCT00001789Phase 21 country